1. Serum High Mobility Group Box 1 Protein as an Early Marker of Pulmonary Arterial Hypertension in Neonates.
- Author
-
Allah Hasan, Beshir Abd, Ahmed, Hanan Samir, Ahmed, Israa Beshir, and El Gebaly, Sherief Mohammed
- Subjects
HIGH mobility group proteins ,PULMONARY arterial hypertension ,PERSISTENT fetal circulation syndrome ,ASPHYXIA neonatorum ,PULMONARY hypertension ,NEWBORN infants ,CONGENITAL heart disease - Abstract
Background: Inflammation plays an important role in neonatal hypoxia-induced organ damage. Newborns with perinatal asphyxia often develop persistent pulmonary hypertension of the neonate. This study aimed to early detection of pulmonary arterial hypertension in newborn to improve patient morbidity and mortality by estimated serum high mobility group box 1 protein (HMGB1) by enzyme-linked immunosorbent assay (ELISA). Methods: This case control study was conducted in Zagazig University Hospital, Pediatric (NICU) and clinical pathology departments, during a period of eight months from March 2020 to January 2021. Following were the three groups into which patients were split: Group 1: fifteen apparently healthy neonates included 11 male and 4 females, group 2: fifteen congenital heart diseases without pulmonary hypertension neonates included 10 male and 5 female and group 3: Fifteen congenital heart diseases with pulmonary hypertension neonates included 10 male and 5 female. Results: There is a statistically significant difference between the groups that were looked at for HMGB1 expression. When compared pairwise, congenital heart diseases (CHD) with pulmonary hypertension and the other groups show a significant difference (the greatest level was in CHD with pulmonary hypertension) hypertension then CHD without pulmonary hypertension then control group). Conclusion: HMGB1 levels in newborns with pulmonary hypertension increased. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF